García-Guzmán, Juan José
Jiménez Heras, José Manuel
López-Iglesias, David
González-Álvarez, Rafael Jesús
Cubillana-Aguilera, Laura
González Macías, Carmen
Fernández Alba, Juan Jesús
Palacios-Santander, José María
Funding for this research was provided by:
Consejería de Salud y Familias, Junta de Andalucía (ITI-0002-2019, ITI-0002-2019, ITI-0002-2019, ITI-0002-2019, PIN-0069-2019)
Universidad de Cádiz (PR2023-07, 3DLACBIOSENS, PR2022-025, SENSPOT, SC2023–001)
Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033)
Universidad de Cadiz
Article History
Received: 3 June 2024
Accepted: 1 August 2024
First Online: 9 August 2024
Declarations
:
: All the studies implying research work applied to biological samples (human blood, plasma, and/or serum) were conducted in accordance with the Declaration of Helsinki, and the aforementioned projects and, consequently, the present study, in accordance with the Spanish regulation ‘Real Decreto 1090/2015, de 4 de diciembre, por el que se regulan los ensayos clínicos con medicamentos, los Comités de Ética de la Investigación con medicamentos y el Registro Español de Estudios Clínicos’, was approved, respectively, by (1) the Research Ethics Committee of Granada (Spain), on February 26, 2020, registry/protocol number 2/2020; (2) the Research Ethics Committee of Granada (Spain), on November 16, 2020, registry/protocol number 09/20; and (3) the Research Ethics Committee of Cadiz (Spain), on May 12, 2023, registry/protocol number 15.23. In all of them, the resolution stated that the aforementioned projects, involving human samples, are viable, that they present sufficient methodological rigor, that the evaluation of economic costs are correct, and that with respect to the ethical aspects, the projects meet the necessary requirements of suitability of the protocol in relation to the objectives of the study.
: The authors declare no competing interests.